Quantum BioPharma Ltd. (NASDAQ: QNTM) is advancing its lead drug candidate, Lucid-MS, toward a randomized, double-blind, placebo-controlled phase 2 trial in multiple sclerosis (MS) after the U.S. Food and Drug Administration (FDA) cleared its Investigational New Drug (IND) application. The clearance marks a significant step for the company and for the MS treatment landscape, as Lucid-MS is a patented, first-in-class, non-covalent inhibitor of peptidyl arginine deiminase 2 (PAD2) designed to target demyelination directly rather than suppress the immune system.
Multiple sclerosis is a chronic, often disabling disease of the central nervous system in which the immune system attacks myelin, the protective sheath around nerve fibers. Current therapies largely focus on modulating or suppressing the immune response, but none directly repair or prevent myelin damage. Lucid-MS's mechanism of action sets it apart: by inhibiting PAD2, it aims to prevent and reverse myelin degradation, the underlying mechanism of MS, as shown in preclinical models. If successful in clinical trials, this approach could represent a paradigm shift in how MS is treated, potentially offering benefits to patients who do not respond adequately to existing immune-based therapies.
The company's research collaboration with Massachusetts General Hospital and Harvard Medical School further underscores its commitment to advancing MS research. The collaboration involves the [¹⁸F]3F4AP PET imaging tracer, which is being evaluated as a method to visualize and measure demyelination. This imaging tool could enhance the ability to diagnose and monitor MS progression, as well as assess the efficacy of treatments like Lucid-MS in clinical trials. The partnership with two leading medical institutions lends additional scientific credibility to Quantum BioPharma's efforts.
Quantum BioPharma is not alone in pursuing innovative therapies for unmet medical needs. The announcement places the company alongside other major players making strides in areas with significant patient demand. Novartis AG (NYSE: NVS) recently received FDA approval for Pluvicto® in combination with an androgen receptor pathway inhibitor for certain patients with metastatic hormone-sensitive prostate cancer. Merck & Co. Inc. (NYSE: MRK) had its supplemental Biologics License Application for ENFLONSIA™ accepted by the FDA to expand its indication for certain children at increased risk for severe respiratory syncytial virus disease. TG Therapeutics Inc. (NASDAQ: TGTX) initiated a phase 2 trial of BRIUMVI® in adults with treatment-resistant schizophrenia. Bristol-Myers Squibb Company (NYSE: BMY) reported positive phase 2 results from the registrational QUINTESSENTIAL trial evaluating arlocabtagene autoleucel in heavily pretreated relapsed and refractory multiple myeloma.
For Quantum BioPharma, the FDA clearance of the IND application is a critical milestone that allows the company to proceed with the Phase 2 trial, which will test the safety and efficacy of Lucid-MS in MS patients. Positive results could pave the way for later-stage trials and eventual regulatory approval, potentially transforming the treatment landscape for MS. The news also highlights the company's broader pipeline and strategic focus. Quantum BioPharma is dedicated to building a portfolio of innovative assets for neurodegenerative and metabolic disorders and alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., the company is focused on the research and development of Lucid-MS.
In addition to its MS program, Quantum invented UNBUZZD™ and spun out its OTC version to Unbuzzd Wellness Inc. (formerly Celly Nutrition Corp.), led by industry veterans. Quantum retains ownership of 19.84% (as of March 31, 2026) of Unbuzzd at www.unbuzzd.com. The agreement with Unbuzzd also includes royalty payments of 7% of sales from unbuzzd™ until payments to Quantum total $250 million. Once $250 million is reached, the royalty drops to 3% in perpetuity. Quantum retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses.
The latest news and updates relating to QNTM are available in the company's newsroom at https://ibn.fm/QNTM. For the full press release, visit https://ibn.fm/lCey9.
